NCT00162201View on ClinicalTrials.gov

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Abatacept

Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.

Trial Locations (1)

Unknown

Local Institution, Leeds

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00162201 - An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy | Biotech Hunter | Biotech Hunter